Đang chuẩn bị liên kết để tải về tài liệu:
Candidate methylation sites associated with endocrine therapy resistance in ER+/ HER2- breast cancer

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. | Candidate methylation sites associated with endocrine therapy resistance in ER HER2- breast cancer